Neurology Daily Report: 01/23/2024

A phase IIIb randomized, double-blind, placebo-controlled study investigated the effect of nabiximols in 64 patients with chronic tic disorders and found that nabiximols did not impair driving skills and even improved fitness to drive in some patients (1). In the nabiximols group, the number of patients fit to drive increased from 24 (55.8%) at baseline to 28 (71.8%) at week 13, whereas in the placebo group, it decreased from 14 (66.7%) to 10 (52.6%). This substudy of the CANNA-TICS trial took place at two study sites.

Reference

Müller-Vahl KR, Pisarenko A, Ringlstetter R, Cimpianu CL, Fremer C, Weidinger E, Jenz EB, Musil R, Brunnauer A, Großhennig A. The Effect of Nabiximols on Driving Ability in Adults with Chronic Tic Disorders: Results of a Substudy Analysis of the Double-Blind, Randomized, Placebo-Controlled CANNA-TICS Trial. Cannabis Cannabinoid Res. 2024 Jan 23. doi: 10.1089/can.2023.0114. Epub ahead of print. PMID: 38265476.